Cargando…
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant pros...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295778/ https://www.ncbi.nlm.nih.gov/pubmed/30574205 http://dx.doi.org/10.1177/1756287218811450 |